A practical reference on CJC-1295: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-27 and is reviewed periodically as new material appears.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
== External links == Olfactory Receptor Database Archived 2007-02-19 at the Wayback Machine Human Olfactory Receptor Data Exploratorium (HORDE) Olfactory+Receptor+Protein at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
In a letter to Chancellor Rachel Reeves, a group of the UK's high street retailers has warned the "cumulative burden" of tax rises announced in the October budget, as well as other policies already in the pipeline, will add billions in costs to the retail sector and put jobs at risk. The UK government estimates that 50,000 pensioners will be living in poverty in 2025 as a result of cuts to winter fuel payments. 20 November Inflation rises from 1.7% to 2.3%, its highest level in six months, driven by rising energy costs. Harrods' newly appointed survivors' advocate Dame Jasvinder Sanghera tells BBC Radio 4's The World at One that Mohamed Al Fayed's sexual abuse could be "something on the scale of Jimmy Savile". UK-supplied Storm Shadow missiles, with a significantly longer range than earlier weapons, are reportedly used for the first time by Ukraine to strike inside Russia. Defence Secretary John Healey announces the early decommissioning of some older defence equipment, such as ships, drones and helicopters in order to save £500m, and despite an "increasing global threat" facing the UK. 21 November A Briton, 28-year-old Simone White, is among those reported to have died in a mass poisoning in Laos. A report by the Charity Commission into activities at the Captain Sir Tom Moore Foundation finds that Hannah and Colin Ingram-Moore (Moore's daughter and son-in-law) benefited from their association with the charity, including money from a £1.4m book deal paid to a family company, not to the Foundation.
The Viceroyalty of New Granada was established in 1717, then temporarily removed, and then re-established in 1739. Its capital was Santa Fé de Bogotá. This Viceroyalty included some other provinces of northwestern South America that had previously been under the jurisdiction of the Viceroyalties of New Spain or Peru and correspond mainly to today's Venezuela, Ecuador, and Panama. Bogotá became one of the principal administrative centers of the Spanish possessions in the New World, along with Lima and Mexico City, though it remained less developed compared to those two cities in several economic and logistical ways. Great Britain declared war on Spain in 1739, and the city of Cartagena quickly became a top target for the British. A massive British expeditionary force was dispatched to capture the city, but, after achieving initial inroads, devastating outbreaks of disease crippled their numbers, and the British were forced to withdraw. The battle became one of Spain's most decisive victories in the conflict, and secured Spanish dominance in the Caribbean until the Seven Years' War. The 18th-century priest, botanist, and mathematician José Celestino Mutis was delegated by Viceroy Antonio Caballero y Góngora to conduct an inventory of the nature of New Granada. Started in 1783, this became known as the Royal Botanical Expedition to New Granada. It classified plants and wildlife, and founded the first astronomical observatory in the city of Santa Fe de Bogotá. In July 1801 the Prussian scientist Alexander von Humboldt reached Santa Fe de Bogotá where he met with Mutis.
Buserelin, sold under the brand name Suprefact among others, is a medication which is used primarily in the treatment of prostate cancer and endometriosis. It is also used for other indications such as the treatment of premenopausal breast cancer, uterine fibroids, and early puberty, in assisted reproduction for female infertility, and as a part of transgender hormone therapy. In addition, buserelin is used in veterinary medicine. The medication is typically used as a nasal spray three times per day, but is also available for use as a solution or implant for injection into fat. Side effects of buserelin are related to sex hormone deprivation and include symptoms of low testosterone levels and low estrogen levels such as hot flashes, sexual dysfunction, vaginal atrophy, and osteoporosis. Buserelin is a gonadotropin-releasing hormone agonist (GnRH agonist) and works by preventing the production of sex hormones by the gonads. It can lower sex hormone levels by about 95% in both sexes. Buserelin is a peptide and an analogue of GnRHTooltip gonadotropin-releasing hormone. Buserelin was first patented in 1974 and approved for medical use in 1985. It is not available in the United States, but is marketed widely elsewhere in the world, including in the United Kingdom, Canada, and many other countries. The medication is one of only two medically used GnRH analogues that are available as nasal sprays, the other being nafarelin. Buserelin is available as a generic medication.
Sources: en.wikipedia.org
In 1931, when he was 16, Thomas left school to become a reporter for the South Wales Daily Post, where he remained for some 18 months. After leaving the newspaper, Thomas continued to work as a freelance journalist for several years, during which time he remained at Cwmdonkin Drive. He continued to add to his notebooks, which would eventually comprise over 200 poems in five books compiled between 1930 and 1935. Of the 90 poems he published, half were written during these years. The discovery in 2014 of the fifth notebook containing 16 poems, compiled between 1934 and August 1935, had substantial implications for the understanding of Thomas's poetic development as well as leading to a revision of the hitherto accepted chronology of composition dates for the poems.
Cofran, Hurst & Hawks (2026) present a virtual reconstruction of the brain endocast of Homo naledi, providing evidence of presence of a combination of ancestral and derived features in the brain of the studied hominin. Madupe et al. (2026) determine the sex of at least 20 individuals of Homo naledi from the Rising Star cave system (Cradle of Humankind, South Africa) on the basis of proteomic analysis of tooth enamel, finding no evidence of male markers in the studied sample. Delagnes et al. (2026) study the mobility of Early Pleistocene hominins from the Lower Omo Valley (Shungura Formation, Ethiopia), providing evidence of transport of quartz for the production of Oldowan stone tools from the alluvial fans of the Hamar Range, over 10 km from the sites preserving the stone tools, located in areas that lacked stone material but had rich faunal assemblages. Evidence from the study of Oldowan tools from the Shungura Formation, indicating that different sediment types produced characteristic wear of the studied tools that can be distinguished wear caused by other types of sediment and from anthropogenic use-wear, is presented by Galland et al. (2026). Dominguez-Rodrigo et al.
Waffle House, Inc. is an American restaurant chain with over 2,000 locations in 25 states in the United States. The bulk of the locations are in the Midwest and the South, where the chain is a regional cultural icon. The menu consists mainly of Southern breakfast food. Waffle House is headquartered in Norcross, Georgia, in the Atlanta metropolitan area.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.